



PRESS RELEASE

Aenova Group initiates restructuring of its management team

Starnberg, 6 October 2015. The Aenova Group, one of the world's leading providers of contract manufacturing and development services to the pharmaceutical industry, has begun restructuring its management team. The Supervisory Board of Aenova Holding has unanimously appointed Dr. Axel Müller to the CEO ad interim with immediate effect. Dr. Müller (age 58) is particularly well acquainted with the company and its strategy. He has held a variety of international management positions in the pharmaceutical industry. Amongst other positions, he was CEO at Acino Holding AG, Switzerland, and at Skyepharma plc., London, and thus has extensive management and industry experience.

Heiner Hoppmann, who has been CEO of Aenova Holding since November 2008, is leaving the company. In addition to Hoppmann, Dr. Friedrich Sernetz, Chief Commercial Officer, and Dr. Birgit Kudlek, Chief Development Officer, will be leaving the company.

Dr. Markus Böning has been CFO of Aenova Holding since August, succeeding Frank Elsen in that position.

For enquiries:

Elisabeth Hartmann
Head of Corporate Communications
Telefon: +49 8151 9987103
Mobil: +49 151 40203739
E-Mail: elisabeth.hartmann@aenova-group.com
Web: www.aenova-group.com